Guardant Health stock has delivered very strong returns over the past few years, yet the signals on what that means for valuation are mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market multiples suggest the shares screen expensive.

• Guardant Health has returned 347.6% over the past three years, which puts extra focus on whether the current share price leaves much margin for error.
• Growing adoption of the Guardant360 and Shield blood tests may support revenue expectations, while the need to keep funding product development and commercial expansion can add risk to how quickly cash flows materialise.
• Guardant Health scores 2 out of 6 on broader valuation checks, so the stock does not screen as a clear bargain even though the DCF suggests it is trading about 24.1% below intrinsic value.

The issue now is whether Guardant Health's recent share price strength is still compatible with an attractive entry point, given these conflicting valuation signals.

Is Guardant Health Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model used here projects the cash that Guardant Health could generate for shareholders over time and then discounts it back to today. Guardant Health currently reports latest twelve month free cash flow of about $232.9 million in outflows, so the model assumes a shift toward growing positive cash flows over the next decade. On those assumptions, the 2 Stage Free Cash Flow to Equity approach points to an estimated intrinsic value of about $215 per share.

Compared with the latest market price, that estimate implies Guardant Health trades at roughly a 24.1% discount, so the stock appears undervalued on this method. The strong Q2 revenue update and raised full year guidance may help explain why analysts are comfortable projecting improvement in future free cash flows, even though the company is still using significant cash today.

On this DCF view, Guardant Health stock looks undervalued relative to what its projected cash flows could justify.

Our Discounted Cash Flow (DCF) analysis suggests Guardant Health is undervalued by 24.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Has Guardant Health Run Too Far on Sales?

P/S is often a cleaner way to compare Guardant Health with other early stage healthcare stocks, because earnings and book value are still affected by heavy investment and reported losses.

Guardant Health currently trades on a P/S of about 18.5x. That is far above the Healthcare industry average of around 1.4x and also well above the peer group average of roughly 1.4x. The Simply Wall St model suggests a tailored fair P/S ratio of about 9.7x, which reflects the company’s revenue profile, size and risk. Against that comparison, the current P/S is almost double the implied fair level.

Even allowing for Guardant Health’s growth ambitions and blood test portfolio, the gap between the present 18.5x P/S and both sector norms and the modelled fair ratio points to a rich valuation on sales.

On the P/S multiple, Guardant Health stock appears clearly overvalued relative to both peers and its own fundamentals.

The Guardant Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Guardant Health pick up where this valuation puzzle leaves off and explain which combinations of future growth, profit margins and earnings would need to occur for the stock to be worth materially more or less than it is today. Each Narrative connects its number to a clear view on how Guardant Health's growth, margins and risks might change over time, so you can revisit those assumptions as new information appears on the Community page.

The community is split on Guardant Health, with one camp focused on the upside from broader screening coverage and another worried that expectations already look stretched.

Bull case: roughly fairly valued

"Substantial regulatory, reimbursement, and clinical validation milestones (including Shield's breakthrough device status, NCCN guideline inclusion, and ongoing pilot studies) are paving the way for further guideline adoption..."

Bear case: 99% overvalued

"Reliance on premium Medicare ADLT pricing for Shield at US$1,495 and very limited commercial reimbursement means any shift in payer mix toward commercial patients or slower than hoped contracting could compress Shield ASPs and limit revenue growth from screening..."

Do you think there's more to the story for Guardant Health? Head over to our Community to see what others are saying!

The Bottom Line

The Discounted Cash Flow (DCF) intrinsic value estimate suggests Guardant Health trades at a meaningful discount to projected cash flows, while the P/S multiple points to an overvalued stock relative to peers. That split largely comes down to how much weight you place on future free cash flow improvement versus what the current revenue multiple already assumes about growth and execution. Broader valuation checks are weak, so the intrinsic value signal sits against a cautious backdrop. The key question from here is whether Guardant Health can convert its testing portfolio into sustained, cash generative growth fast enough to justify both the current price and the more optimistic view among analysts and investors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.